Related Experiment Video
Updated: Jun 4, 2026

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
Published on: June 23, 2023
Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death
Dong-Hee Choi1, Youn-Jung Kim, Young-Gun Kim
1Neurology/Neuroscience Department, Weill Medical College of Cornell University, New York, New York 10065, USA.
Abstract:
Evidence suggests that the C-terminal truncation of α-synuclein is equally important as aggregation of α-synuclein in Parkinson disease (PD). Our previous results showed that an endopeptidase, matrix metalloproteinase-3 (MMP3), was induced and activated in dopaminergic (DA) cells upon stress conditions. Here, we report that MMP3 cleaved α-synuclein in vitro and in vivo and that α-synuclein and MMP3 were co-localized in Lewy bodies (LB) in the postmortem brains of PD patients. Incubation of α-synuclein with the catalytic domain of MMP3 (cMMP3) resulted in generation of several peptides, and the peptide profiles of WT α-synuclein (WTsyn) and A53T mutant (A53Tsyn) were different. Combined analysis using mass spectrometry and N-terminal determination revealed that MMP3 generated C-terminally truncated peptides of amino acids 1-78, 1-91, and 1-93 and that A53Tsyn produced significantly higher quantities of these peptides. Similar sizes of peptides were detected in N27 DA cells under oxidative stress and RNA interference to knock down MMP3-attenuated peptide generation. Co-overexpression of cMMP3 with either WTsyn or A53Tsyn led to a reduction in Triton X-100-insoluble aggregates and an increase in protofibril-like small aggregates. In addition, overexpression of the 1-93-amino acid peptide in the substantia nigra led to DA neuronal loss without LB-like aggregate formation. The results strongly indicate that MMP3 digestion of α-synuclein in DA neurons plays a pivotal role in the progression of PD through modulation of α-synuclein in aggregation, LB formation, and neurotoxicity.
Insights
Matrix metalloproteinase-3 (MMP3) cleaves alpha-synuclein in Parkinson disease (PD) brains. This MMP3 digestion generates toxic fragments, contributing to neurodegeneration and Lewy body formation in PD.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Alpha-synuclein aggregation and C-terminal truncation are implicated in Parkinson disease (PD).
- Matrix metalloproteinase-3 (MMP3) is activated in dopaminergic (DA) cells under stress.
Purpose of the Study:
- To investigate the role of MMP3 in cleaving alpha-synuclein in PD.
- To determine the impact of MMP3-mediated alpha-synuclein cleavage on aggregation, Lewy body formation, and neurotoxicity.
Main Methods:
- In vitro cleavage assays using purified alpha-synuclein and MMP3 catalytic domain (cMMP3).
- Mass spectrometry and N-terminal determination to identify cleavage products.
- Analysis of peptides in N27 DA cells under oxidative stress and MMP3 knockdown.
- In vivo studies involving co-overexpression of cMMP3 and alpha-synuclein variants, and peptide overexpression in the substantia nigra.
Main Results:
- MMP3 cleaves alpha-synuclein in vitro and in vivo, generating C-terminally truncated peptides (1-78, 1-91, 1-93).
- A53T mutant alpha-synuclein produced higher quantities of these truncated peptides.
- MMP3 knockdown attenuated peptide generation in stressed DA cells.
- Co-overexpression of cMMP3 reduced insoluble aggregates but increased small aggregates.
- Overexpression of the 1-93 peptide caused DA neuronal loss without Lewy body formation.
Conclusions:
- MMP3-mediated cleavage of alpha-synuclein is a key event in PD pathogenesis.
- This process influences alpha-synuclein aggregation, Lewy body formation, and DA neurotoxicity.
- Targeting MMP3 activity may offer a therapeutic strategy for Parkinson disease.
Related Concept Videos
Role of Matrix Metalloproteases in Degradation of ECM
A...
Parkinson Disease ll: Pathophysiology
